Welcome to our dedicated page for ArriVent BioPharma SEC filings (Ticker: AVBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ArriVent BioPharma, Inc. filings document a Nasdaq-listed clinical-stage oncology company with common stock registered under the Exchange Act. Its Form 8-K reports cover financial results, Regulation FD disclosures, clinical and preclinical program announcements, conference presentations, IND-related updates, material-event disclosures, and exhibits tied to press releases.
Proxy materials describe stockholder voting matters, board elections, auditor ratification, annual meeting procedures, and governance information. The filing record also reflects capital-structure disclosures, emerging growth company status, material agreements, and risk-oriented disclosures associated with ArriVent's firmonertinib program and antibody-drug conjugate pipeline.
ArriVent BioPharma, Inc. reported continued operating losses as it advances oncology programs, led by EGFR inhibitor firmonertinib and ADC ARR-217. For the six months ended June 30, 2026, the company recorded a net loss of $93.2 million, slightly improved from $95.8 million a year earlier. Research and development expenses were $80.0 million versus $89.0 million, reflecting lower early-stage program spend after a prior-year $40.0 million upfront payment, partly offset by higher Phase 3 trial and personnel costs. General and administrative expenses increased to $18.8 million from $11.4 million due to headcount and professional services.
Cash, cash equivalents and short-term investments totaled $373.1 million as of June 30, 2026, which the company states is sufficient to fund planned operations for at least twelve months from the financial statement issuance date. Liquidity was strengthened by $140.0 million in net proceeds from sales of 5,358,318 common shares under an at-the-market program, and an undrawn $75.0 million term loan facility. ArriVent also disclosed significant contingent milestone and royalty obligations under multiple licensing and collaboration agreements and outlined a new collaboration and license arrangement granting Allist rights to ARR-002 in Greater China.
ArriVent BioPharma, Inc. entered a Collaboration and License Agreement with Shanghai Allist Pharmaceuticals, granting Allist an exclusive, sublicensable, royalty-bearing license to develop and commercialize ARR-002 in Greater China, while ArriVent retains rights elsewhere and a right to manufacture in the territory. ArriVent may receive up to $80.6 million in upfront and milestone payments, plus tiered royalties in the mid-single digit to low double-digit range on ARR-002 net sales in the licensed territory, with royalties payable for a defined patent, regulatory, or time-based royalty term.
For the quarter ended June 30, 2026, ArriVent reported a net loss of $49.9 million on operating expenses of $52.7 million, compared with a $31.4 million net loss a year earlier. For the first six months of 2026, net loss was $93.2 million, slightly improved from $95.8 million in the prior-year period as total operating expenses declined. The company ended June 30, 2026 with $154.7 million in cash and cash equivalents, $218.4 million in short-term investments, and total stockholders’ equity of $366.8 million, providing substantial capital to advance firmonertinib and its ADC pipeline, including ARR-217 and ARR-002.
BlackRock, Inc. reports beneficial ownership of common stock of Arrivent Biopharma Inc. on an amended Schedule 13G. BlackRock and certain of its business units collectively hold 3,182,080 shares, representing 6.8% of the common stock outstanding.
BlackRock reports sole voting power over 3,130,621 shares and sole dispositive power over 3,182,080 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Arrivent Biopharma’s outstanding common shares.
ArriVent BioPharma, Inc. director Parsey Merdad received a grant of non-qualified stock options covering 13,562 shares of common stock. The options have an exercise price of $31.74 per share and expire on June 17, 2036.
The shares underlying this option vest on the first anniversary of the June 18, 2026 grant date, subject to his continued service through the vesting date. Following this award, he holds 13,562 derivative securities directly.
ArriVent BioPharma director Kristine Peterson received a new stock option grant. She was awarded a non-qualified option covering 13,562 shares of common stock at an exercise price of $31.74 per share. The option vests on the first anniversary of the grant date, contingent on her continued service, and expires on June 17, 2036. Following this grant, she holds 13,562 derivative securities directly from this award.
ArriVent BioPharma, Inc. director John Hohneker received a grant of non-qualified stock options covering 13,562 shares of common stock. The options have an exercise price of $31.74 per share, expire on June 17, 2036, and vest on the first anniversary of the June 18, 2026 grant date, subject to continued service.
ArriVent BioPharma director Chris Nolet received a grant of non-qualified stock options covering 13,562 shares of common stock. The options have an exercise price of $31.74 per share and expire on June 17, 2036. The underlying shares vest on the first anniversary of the June 18, 2026 grant date, conditioned on continued service.
ArriVent BioPharma, Inc. reported results of its 2026 annual meeting of stockholders held via live webcast. Stockholders elected three Class II directors—James Healy, M.D., Ph.D., John Hohneker, M.D., and Stuart Lutzker, M.D., Ph.D.—to serve until the 2029 annual meeting.
Of 46,368,442 common shares eligible to vote as of April 21, 2026, 33,418,793 shares, or 72.07%, were present or represented by proxy, satisfying quorum requirements. Stockholders also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
ArriVent BioPharma, Inc. filed a prospectus supplement tied to its existing at-the-market equity offering program. Under this supplement, the company may offer and sell shares of its common stock with an aggregate offering price of up to $250,000,000 from time to time through Jefferies LLC as sales agent.
The at-the-market sales are made under an Open Market Sale Agreement dated February 3, 2025, and are covered by ArriVent’s automatic shelf registration statement on Form S-3ASR, which became effective upon filing. The company also filed the sales agreement and related legal opinions as exhibits.
ArriVent BioPharma, Inc. is offering up to $250,000,000 of its common stock in an “at the market” (ATM) program through Jefferies LLC as sales agent. Shares may be sold from time to time at market prices; Jefferies may receive commissions up to 3.0%. The prospectus supplement cites a last reported sale price of $29.50 per share (May 8, 2026), and illustrates an issuance of 8,474,576 shares at that price. The document states shares outstanding were 45,308,941 as of March 31, 2026 and presents net tangible book value of $301.1 million (or $6.64 per share) and an illustrative as‑adjusted net tangible book value of $544.7 million (or $10.12 per share) after the assumed $250.0 million ATM sale. Net proceeds are stated to be used to support development of firmonertinib, other pipeline programs and general corporate purposes. Sales under the agreement are conditional, may occur at varying prices and times, and Jefferies may terminate or decline transaction instructions per the sales agreement terms.